Bulk Pharmaceutical API Sources for VERMIDOL

Bulk Pharmaceutical API Sources for VERMIDOL

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		114763
AAA Chemistry		AR-1L1011
ABI Chem		AC1L3FX5
ABI Chem		AC1Q5SNX
Ark Pharm, Inc.		AK-47855

Bulk Active Pharmaceutical Ingredient (API) Sources for VERMIDOL

Last updated: February 19, 2026

This report identifies and analyzes key bulk active pharmaceutical ingredient (API) manufacturers and suppliers for VERMIDOL, a broad-spectrum anthelmintic. The analysis focuses on production capacity, regulatory compliance, and geographical distribution to inform strategic sourcing decisions for pharmaceutical companies.

What is VERMIDOL?

VERMIDOL is the proprietary name for a benzimidazole derivative used to treat parasitic worm infestations in humans and animals. Its mechanism of action involves binding to parasitic beta-tubulin, disrupting microtubule polymerization and inhibiting glucose uptake, leading to parasite immobilization and death. The primary API is Albendazole.

Key API Manufacturers and Suppliers

The global market for Albendazole API is characterized by a mix of established pharmaceutical ingredient manufacturers and specialized contract manufacturing organizations (CMOs). Key players are primarily located in India and China, driven by cost advantages and a well-developed API manufacturing infrastructure.

Table 1: Major Albendazole API Suppliers

Company Name	Country of Origin	Primary Product Focus	Regulatory Approvals (Examples)	Key Strengths
Sun Pharmaceutical Industries Ltd.	India	Generic APIs, Finished Dosage Forms	US FDA, EDQM, WHO GMP	Large-scale production, established supply chain
Dr. Reddy's Laboratories Ltd.	India	Diverse Generic APIs	US FDA, EMA, Health Canada	R&D capabilities, global distribution network
IOL Chemicals and Pharmaceuticals Ltd.	India	APIs (including Albendazole)	US FDA, EDQM, KFDA	Cost-competitiveness, high volume output
Shasun Pharmaceuticals Ltd. (Merck Group)	India	Contract Manufacturing, APIs	US FDA, EDQM, PMDA	Strong regulatory track record, technical expertise
Zhejiang NHU Co., Ltd.	China	APIs, Vitamins, Nutritionals	US FDA, EDQM, COFEPRIS	Significant production capacity, competitive pricing
CSPC Pharmaceutical Group Limited	China	Broad API Portfolio	US FDA, EDQM, SFDA	Extensive manufacturing facilities, integrated operations

Source: Publicly available company information, regulatory databases, industry reports. Specific approval details may vary by site and product.

Indian API Manufacturers

India remains a dominant force in global API production, including Albendazole. Companies benefit from skilled labor, established regulatory pathways, and strong government support for the pharmaceutical sector.

• Sun Pharmaceutical Industries Ltd. is a leading Indian pharmaceutical company with substantial API manufacturing capabilities. Its facilities are regularly inspected by major regulatory bodies, ensuring compliance for global markets. They have a proven track record of supplying high-volume APIs.
• Dr. Reddy's Laboratories Ltd. is another major player, known for its robust R&D and manufacturing prowess. Their API division supplies a wide range of active ingredients, and their commitment to quality is reflected in their numerous regulatory certifications.
• IOL Chemicals and Pharmaceuticals Ltd. is a significant producer of bulk chemicals and pharmaceuticals, with Albendazole being a key product. The company emphasizes cost-effective production without compromising on quality, making it an attractive source for high-volume demand.
• Shasun Pharmaceuticals Ltd., now part of the Merck Group, has a strong reputation for contract manufacturing and API development. Their expertise in complex synthesis and adherence to stringent quality standards are notable.

Chinese API Manufacturers

Chinese API manufacturers have grown significantly in scale and regulatory sophistication, offering competitive pricing for Albendazole. While historically concerns existed regarding quality and regulatory adherence, leading Chinese manufacturers now meet international standards.

• Zhejiang NHU Co., Ltd. is a large, diversified chemical and pharmaceutical company with significant API production. Their scale of operations allows for competitive pricing, and they have invested in quality systems to meet global regulatory expectations.
• CSPC Pharmaceutical Group Limited operates a vast network of manufacturing sites and produces a wide array of APIs. Their integrated approach, from raw material sourcing to finished API, can offer supply chain advantages.

Regulatory Landscape and Compliance

The production of Albendazole API for pharmaceutical use is subject to strict regulatory oversight to ensure patient safety and product efficacy. Key regulatory bodies and standards include:

• U.S. Food and Drug Administration (US FDA): Requires Current Good Manufacturing Practices (cGMP) compliance. Facilities are subject to regular inspections.
• European Medicines Agency (EMA) / European Directorate for the Quality of Medicines & HealthCare (EDQM): Requires Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). EDQM audits manufacturing sites.
• World Health Organization (WHO): WHO GMP certification is often a prerequisite for supply to many developing countries.
• Other National Regulatory Authorities: Such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, and national agencies in India, China, and Brazil.

Manufacturers must maintain robust quality management systems, validate all manufacturing processes, and control impurities within pharmacopoeial limits (e.g., USP, EP, JP). The impurity profile of an API is critical and can impact regulatory approval of finished drug products.

Table 2: Key Regulatory Requirements for Albendazole API

Requirement Category	Description	Impact on Sourcing Decisions
cGMP Compliance	Adherence to Good Manufacturing Practices as defined by regulatory bodies (US FDA, EMA, WHO, etc.).	Manufacturers must demonstrate robust quality systems, documented procedures, trained personnel, and validated processes. Sourcing from FDA-inspected or EDQM-certified facilities is essential for key markets.
Pharmacopoeial Standards	Albendazole must meet specifications outlined in major pharmacopoeias (USP, EP, JP, IP).	Suppliers must provide Certificates of Analysis (CoA) confirming compliance with relevant pharmacopoeial monographs, including tests for identity, assay, impurities, and physical characteristics.
Impurity Profiling	Identification, quantification, and control of process-related and degradation impurities.	Manufacturers need well-characterized impurity profiles. Novel or significant impurities may require toxicological assessment and specific regulatory filings. Understanding the impurity profile of an API from a new supplier is a critical due diligence step.
Stability Data	Comprehensive stability studies demonstrating the API's shelf-life under specified storage conditions.	Reliable stability data is necessary for establishing expiry dates and storage conditions for both the API and the finished drug product.
Drug Master File (DMF)	Submission to regulatory authorities detailing manufacturing processes, quality control, and facility information.	A filed DMF (e.g., US DMF, EU DMF) facilitates the review process for finished drug product applications. Suppliers with accessible DMFs streamline the regulatory pathway.
Supply Chain Security	Measures to prevent counterfeiting, diversion, and contamination throughout the supply chain.	Requires transparency in sourcing and robust handling procedures. Verification of supplier's logistics and security protocols is important.
Environmental, Social, Governance (ESG)	Increasing focus on sustainable manufacturing practices, ethical labor, and corporate responsibility.	While not always a direct regulatory requirement, ESG factors are increasingly important for corporate partnerships and investor relations. Suppliers with demonstrated ESG commitments may offer long-term strategic advantages.

Production Capacity and Market Dynamics

The global demand for Albendazole API is driven by its widespread use in both human and veterinary medicine, particularly in regions with high parasitic infection rates. While demand is relatively stable, fluctuations can occur based on public health initiatives, agricultural needs, and the introduction of new treatment protocols.

• Capacity: Major Indian and Chinese manufacturers possess the capacity to produce hundreds of metric tons of Albendazole API annually. This scale provides a buffer against supply chain disruptions and allows for competitive pricing.
• Pricing: Prices for bulk Albendazole API are influenced by raw material costs, manufacturing efficiency, regulatory compliance investments, and competitive pressures among suppliers. Current market prices for pharmaceutical-grade Albendazole API typically range from $30 to $70 per kilogram, depending on volume, quality certifications, and supplier.
• Supply Chain Risks: Geopolitical instability, natural disasters, and unexpected regulatory changes can impact the supply chain. Diversifying the supplier base across different geographical regions can mitigate these risks. For Albendazole, reliance on a few key manufacturers or countries can create vulnerabilities.
• Contract Manufacturing: Pharmaceutical companies often engage CMOs for API production. This can provide flexibility in production volumes and allow companies to focus on formulation, marketing, and distribution. Key CMOs with expertise in benzimidazole synthesis are critical partners.

Geographic Considerations

The primary manufacturing hubs for Albendazole API are India and China.

• India: Benefits from a well-established regulatory framework, a skilled workforce, and significant government support for the pharmaceutical industry. Indian manufacturers are often preferred for their strong regulatory compliance and consistent quality.
• China: Offers highly competitive pricing due to economies of scale and lower manufacturing costs. However, due diligence regarding quality control and regulatory adherence is paramount when sourcing from China.

Emerging manufacturing capabilities in other regions, such as Southeast Asia or Eastern Europe, may offer future diversification opportunities, but currently, the bulk of global supply originates from India and China.

Due Diligence for API Sourcing

When selecting a supplier for Albendazole API, pharmaceutical companies should conduct thorough due diligence, including:

1. Regulatory Audit: Verify current GMP certifications, inspection history with major regulatory bodies (US FDA, EMA, WHO), and the status of any DMF filings.
2. Quality Control Assessment: Review the supplier's Quality Management System (QMS), analytical testing capabilities, and impurity control strategies. Request sample batches for internal testing.
3. Production Capacity and Reliability: Assess the supplier's current capacity, historical production performance, and their ability to scale up to meet future demand. Inquire about their business continuity plans.
4. Financial Stability: Evaluate the financial health of the potential supplier to ensure long-term partnership viability.
5. Supply Chain Transparency: Understand the supplier's raw material sourcing, logistics, and any sub-contracting arrangements.
6. Intellectual Property: For novel applications or formulations, ensure no IP infringements.

Key Takeaways

• Albendazole API is primarily manufactured in India and China, with Indian suppliers generally having stronger and longer-standing regulatory track records for major Western markets.
• Regulatory compliance, particularly adherence to cGMP and pharmacopoeial standards, is critical for ensuring product quality and patient safety.
• Key manufacturers like Sun Pharma, Dr. Reddy's, IOL Chemicals, Zhejiang NHU, and CSPC hold significant production capacities.
• Pricing is competitive, influenced by production scale, raw material costs, and global demand.
• Thorough due diligence covering regulatory audits, quality assessments, and supply chain reliability is essential for strategic sourcing.

FAQs

1. What are the primary regulatory hurdles for sourcing Albendazole API for the US market? Manufacturers must comply with US FDA cGMP regulations. This includes having a facility that has passed FDA inspections and potentially having a filed US Drug Master File (DMF) for the API.

2. How does the impurity profile of Albendazole API affect its sourcing? Impurity profiles are critical. Any impurities exceeding pharmacopoeial limits or representing new chemical entities require rigorous toxicological assessment and regulatory scrutiny. Suppliers must provide detailed impurity data and robust control strategies.

3. What is the typical lead time for sourcing bulk Albendazole API from major manufacturers? Lead times can vary from 2 to 12 weeks, depending on order volume, current production schedules, and supplier inventory. Urgent orders may incur premium pricing or require expedited shipping.

4. Are there significant differences in quality between Albendazole API sourced from India versus China? While both countries produce API meeting pharmacopoeial standards, the rigor and history of regulatory compliance for major Western markets are generally more established with leading Indian manufacturers. However, many Chinese manufacturers have significantly improved their quality systems and regulatory adherence.

5. What are the long-term supply chain risks associated with Albendazole API? Long-term risks include reliance on a limited number of key suppliers or geographic regions (India/China), potential raw material price volatility, and unexpected regulatory changes or geopolitical events impacting manufacturing or export. Diversification of suppliers is a key mitigation strategy.

Citations

[1] Sun Pharmaceutical Industries Ltd. (n.d.). API Capabilities. Retrieved from [Company Website] [2] Dr. Reddy's Laboratories Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Company Website] [3] IOL Chemicals and Pharmaceuticals Ltd. (n.d.). Products. Retrieved from [Company Website] [4] Merck Group. (n.d.). Shasun Pharmaceuticals. Retrieved from [Company Website] [5] Zhejiang NHU Co., Ltd. (n.d.). Products. Retrieved from [Company Website] [6] CSPC Pharmaceutical Group Limited. (n.d.). Product Portfolio. Retrieved from [Company Website] [7] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [FDA Website] [8] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability. Retrieved from [EDQM Website] [9] World Health Organization. (n.d.). WHO Good Manufacturing Practices. Retrieved from [WHO Website]